Clinical trial · Interventional
Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation
NCT03265496CI-TRIAL-00105759CONCORDEterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The number of recruted patient was not sufficient
Summary
Brief summary (as posted)
Condorde main objective is to evaluate the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed on ctDNA after liquid biopsy. EGFR status will be assessed by real time PCR (rtPCR), digital PCR (dPCR) and Next Generation Sequencing (NGS) in patients with chemotherapy naive lung carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nsclc | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1st line treatment | Drug | — | UNRESOLVED |
| Biopsy | Biological | — | UNRESOLVED |
| Clinical exam | Procedure | — | UNRESOLVED |
| Diagnostic exam | Procedure | — | UNRESOLVED |
| Liquid biopsy | Procedure | — | UNRESOLVED |
| tumor evaluation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- study procedure
- description
- Clinical exam. Liquid biopsy. Diagnostic exam (biopsy and imagery). 1st line treatment. tumor evaluation. Biopsy
- interventionNames
- Procedure: Clinical exam
- Procedure: Liquid biopsy
- Procedure: Diagnostic exam
- Drug: 1st line treatment
- Procedure: tumor evaluation
- Biological: Biopsy
Primary outcomes (1)
- measure
- Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At diagnostic. NGS.
- timeFrame
- Baseline
- description
- For patient with mutant EGFR. Evaluate, by next generation sequencing at diagnostic, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years * Metastatic lung carcinoma * With: - EGFR gene mutation * Or at least 2 predictive factors of addictive mutation (Women, non smocking or cessation \> 3 years, Asiatic, lung adenocarcinoma) * Eligible for 1st line treatment * Performance status ≤ 3 * Available tumor sample or tumor reachable for biopsy * With informed and signed consent * Affiliation to the National Social Security System Exclusion Criteria: * Previous radiotherapy treatment in months preceding initials samples * Pregnant or breastfeeding women * Patient not able to give consent or unwilling to provide consent
References
Publications (0)
Data not yet available
No reference posted for this study.